Skip to main content
Loading

Expansion of Neurodegenerative Disease Targets and Pipelines

October 15, 2024
Venetian Room
Advances in neurodegenerative science have pointed to new paths in the development of medicines that have the potential to dramatically improve patient quality of life. These advances are contributing to innovative therapeutic approaches to diseases like Parkinson’s, ALS, and Alzheimer’s. This session will feature leading innovators who will discuss the latest advancements in diverse approaches to neurodegenerative diseases. Attendees will learn about the evolving landscape of neurodegenerative disease research and development, the potential of novel targets, and the implications for future treatment and investment opportunities.​
Moderator
Selina Koch, Executive Editor, Head of Intelligence & Research - BioCentury
Speakers
Kasper Roet - PhD, Founder, Chief Executive Officer - QurAlis Corporation
Karen Harris, Chief Financial Officer & Head of Mission Related Investments - Alzheimer’s Drug Discovery Foundation
Beth Hoffman - PhD, Founder and CEO - Origami Therapeutics, Inc.
David Bearss - PhD, CEO - Halia Therapeutics
Paul August - PhD, Chief Scientific Officer - ReviR Therapeutics

DOUBLE HELIX SPONSOR

HELIX SPONSOR

PREMIER SPONSOR

CONFERENCE SPONSORS